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Cachexia  is  a prevalent  phenomenon  of  non-small  cell  lung  cancer  (NSCLC)  which  is  responsible  for
increased  mortality  and  deterioration  of physical  performance.  Preclinical  research  indicates  that  sys-
temic inﬂammation  induces  cachexia-related  muscle  wasting  through  muscular  Nuclear  Factor-kappa
B  (NF-B)  signaling  and  subsequent  ubiquitin  proteasome  system  (UPS)-mediated  proteolysis.  As  these
pathways  could  be  a target  for  early  intervention  strategies,  it needs  to  be  elucidated  whether  increased
activation  of  these  pathways  is already  present  in  early  stage  NSCLC  cachexia.  The  aim  of the  present
study  was  therefore  to assess  muscular  NF-B  and UPS  activation  in patients  with  NSCLC  pre-cachexia.
Sixteen  patients  with  newly  diagnosed  stages  I–III  NSCLC  having  <10%  weight  loss  and  ten  healthy
controls  were  studied.  Body  composition,  systemic  inﬂammation  and  exercise  capacity  were  assessed  in
all  subjects  and  NF-B  and  UPS  activity  in  vastus  lateralis  muscle  biopsies  in  a subset.
Patients  showed  increased  plasma  levels  of  C-reactive  protein  (CRP)  (P  < 0.001),  soluble  Tumor  Necrosis
Factor  receptor  1  (sTNF-R1)  (P  < 0.05),  ﬁbrinogen  (P  < 0.001)  and  decreased  levels  of  albumin  (P  <  0.001).
No changes  in fat free  body  mass  or  skeletal  muscle  NF-B  and  UPS  activity  were  observed,  while  peak
˙
keletal muscle
oxygen  consumption  (VO2 peak) was  signiﬁcantly  decreased  in  patients  compared  with  healthy  controls.
In  conclusion,  this  exploratory  study  demonstrates  signiﬁcantly  reduced  exercise  capacity  in  NSCLC
pre-cachexia  despite  maintenance  of  muscle  mass  and  unaltered  indices  of  UPS  activation.  The  absence
of muscular  NF-B-dependent  inﬂammatory  signaling  supports  the  notion  that  transition  of systemic  to
local  inﬂammation  is  required  to  initiate  UPS-dependent  muscle  wasting  characteristic  for  (experimental)
cachexia.
. Introduction
Cachexia is a prevalent feature of non-small cell lung cancer
NSCLC) which is characterized by progressive body weight loss
nd peripheral tissue wasting [1].  The signiﬁcance of cachexia in
SCLC is established by its negative impact on therapy respon-
iveness and survival [2–5]. Other important consequences are a
ecline in quality of life and progressive impairment of physical
unction [1,4]. Despite the importance, cachexia in NSCLC remains
ften unrecognized and no adequate management strategies are
vailable [5,6].
∗ Corresponding author at: Department of Respiratory Medicine, NUTRIM School
or  Nutrition, Toxicology & Metabolism, Maastricht University Medical Centre+, P.O.
ox 5800, 6202 AZ Maastricht, The Netherlands. Tel.: +31 43 3881631;
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Skeletal muscle atrophy is identiﬁed as the most important pre-
dictor of mortality and functional impairment in cancer cachexia
[1]. Wasting of skeletal muscle tissue is considered to be induced
by tumor-associated systemic inﬂammation, which subsequently
triggers degradation of skeletal muscle proteins and thereby caus-
ing muscle atrophy [7,8]. Preclinical research has demonstrated
that muscular Nuclear Factor-kappa B (NF-B) integrates systemic
inﬂammatory signals and is responsible for activation of the pro-
teolytic ubiquitin (Ub) proteasome system (UPS) [9,10]. In the
UPS, E1 enzymes and highly speciﬁc E2 Ub-conjugating and E3
Ub-ligating enzyme complexes attach a polyubiquitin chain to pro-
tein substrates. This marks the protein for degradation by the 26S
proteasome 11. In experimental models of cancer cachexia, the
muscle-speciﬁc E3 Ub-ligases Atrogin-1/MAFbx and muscle RING-
Open access under the Elsevier OA license.ﬁnger protein-1 (MuRF1) have shown to be rate limiting in the
degradation of skeletal muscle proteins [12]. Although increased
NF-B and UPS activation plays a predominant role in preclini-
cal cancer cachexia, limited data is available on involvement of
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hese pathways in human cancer cachexia and the onset of putative
ctivation in particular.
Although it is evident that cancer cachexia occurs in progressive
tages of severity, international experts have agreed upon a clear
eﬁnition of distinct clinical stages only recently (Lancet Oncology,
ay  2011) [1].  In the present deﬁnition, three clinically rele-
ant stages of cancer cachexia are distinguished, i.e. pre-cachexia,
achexia and refractory cachexia. Pre-cachexia is considered an
nitial phase in which metabolic changes, such as systemic inﬂam-
ation, have resulted in minor body weight loss but not (yet) in
igniﬁcant depletion skeletal muscle mass or impairment of physi-
al function. Pre-cachexia often progresses to (refractory) cachexia,
ith detrimental effects on survival and performance status. In
he international consensus, it is speciﬁcally emphasized that pre-
achexia should be the focus of clinical and translational research,
s preventive measures in pre-cachexia might delay or prevent pro-
ression to (refractory) cachexia [1,5]. To address this, we studied
f skeletal muscle NF-B and UPS activity is (already) increased
n NSCLC pre-cachexia. As increased activity of these markers
lays a pivotal role in advanced preclinical cachexia, these molec-
lar markers might be important elements for early intervention
trategies in pre-cachectic patients. We  hypothesized that systemic
nﬂammation already initiates muscular NF-B and UPS activation
n pre-cachexia but has not yet resulted in signiﬁcant effects on
ody composition or exercise capacity.
. Subjects and methods
.1. Study population
Sixteen newly diagnosed pre-cachectic patients with locally
advanced) NSCLC consecutively admitted to the department of
espiratory Medicine of the Maastricht University Medical Centre+
nd ten healthy controls were included. Pre-cachexia was  deﬁned
s <10% loss of total body weight in the last six months as the cut-
ff of 10% weight loss was often used to distinguish pre-cachexia
rom clinical cachexia before the recent deﬁnition of pre-cachexia
as published [1]. NSCLC was conﬁrmed by pathological analysis
nd tumor stage was assessed using the tumor-node-metastasis
TNM) International Staging System for Lung Cancer [13]. Exclusion
riteria were the presence of other malignancies or previous admin-
stration of anti-tumor treatment. Age-matched healthy control
ubjects were recruited from advertisements in local newspapers.
he study was approved by the local medical ethical committee and
ritten informed consent was obtained from all subjects.
.2. Pulmonary function and body composition
Spirometry was performed in all subjects to determine the
orced expiratory volume in one second (FEV1) and forced vital
apacity (FVC). Dual energy X-ray absorptiometry (DXA; DPX-L,
unar Radiation Corp., Madison, WI)  was used to determine body
omposition, i.e. fat mass (FM) and fat free body mass (FFM) [14].
XA measurements were performed in the fasted state.
.3. Exercise capacity and physical activity
Exercise capacity testing was performed using an electri-
ally braked cycle ergometer (Corival 400, Lode, Groningen, The
etherlands). The test started with 1 min  of unloaded cycling, after
hich the load was increased by 10 W every minute in patients. Forontrol subjects, the load was increased by 15–25 W every minute
o achieve comparable test duration. None of the subjects knew
he exercise load and all were encouraged to cycle at 60 rpm until
xhaustion. Peak oxygen consumption (V˙O2 peak) was  measured atancer 76 (2012) 112– 117 113
the moment of cessation of the exercise. Predictive values were cal-
culated according to Jones (0.046 (Height) – 0.021 (Age) – 0.62 (Sex:
0, male; 1, female) – 4.31 l/min) [15]. Peak ventilatory (VE) reserve
was  calculated as 100% − (100 × peak VE)/(FEV1 × 37.5) [16]. The
level of physical activity during daily life was measured using a
triaxial accelerometer (Tracmor; Philips Research, Eindhoven, The
Netherlands), which measures body accelerations in anterioposte-
rior, mediolateral, and vertical directions and expresses them in
‘counts’ per time interval (min) [17]. Tracmor data was  obtained
for 7 consecutive days during waking hours for at least 8 h. The
time spent in each category of intensity (low, moderate and high)
is presented as percentage of total wear time.
2.4. Plasma inﬂammatory markers
After an overnight fast, blood from an antecubital vein was
collected in evacuated ethylenediaminetetraacetic acid (EDTA)
blood collection tubes (Sherwood Medical, Ballymoney, Northern
Ireland). Plasma was  obtained by centrifugation of the blood at
3000 Relative Centrifugal Force (RCF) for 15 min  at 4 ◦C. Blood sam-
ples were stored at −80 ◦C until sample analysis was  performed.
Plasma C-reactive protein (CRP) levels were assessed using tur-
bidimetry. Soluble Tumor Necrosis Factor receptor 1 (sTNF-R1)
levels were determined by sandwich ELISA as described elsewhere
[18]. Recombinant human sTNF-R1 was used as standard. Albumin
levels were measured using the Bromocresol Purple method with a
Synchron CX-7 instrument (Beckman, Mijdrecht, The Netherlands).
2.5. Muscle biopsies
Of ten patients, adequate amounts of muscle tissue were avail-
able for molecular analysis. Percutaneous muscle biopsies of m.
vastus lateralis were obtained under general anesthesia prior to
thoracic surgery (N = 5) or local anesthesia (N = 5). Eight healthy
control subjects underwent muscle biopsies under local anesthe-
sia. The technique used for the muscle biopsies was described
by Bergström [19]. Muscle biopsies were immediately frozen in
liquid nitrogen and stored at −80 ◦C until sample analysis was
performed. Muscle biopsies were homogenized using a Polytron
PT1600E homogenizer (Kinematica, Littau-Lucerne, Switzerland).
2.6. Muscle mRNA analysis
Total RNA was isolated using the Totally RNATM kit (Ambion,
Austin, TX, USA) according to manufacturer’s instructions. 0.4 g
RNA was  reverse transcribed to cDNA using the Reverse iT First
Strand Synthesis kit (ABgene, Epsom, UK) with anchored oligo-dT
primers. mRNA expression levels of NF-B-dependent inﬂamma-
tory signaling markers (IkappaBalpha (IB) and Tumor Necrosis
Factor alpha (TNF-)), UPS rate limiting E3 Ub-ligases (Atrogin-
1/MAFbx and MuRF1) and housekeepers (-actin, Cyclophilin,
2-microglobulin) were determined by quantitative RT-PCR (Q-
PCR). Q-PCR primers were designed using Primer Express 2.0
software (Applied Biosystems, Foster City, CA, USA) and obtained
from Sigma Genosys (Haverhill, UK). PCR reactions contained 1×
Q-PCR MasterMix Plus for SYBR green I (ABgene, Epsom, UK) and
6 pmol of each primer (20 l total volume) and were performed in a
MyiQ thermocycler (Bio-Rad, Veenendaal, The Netherlands). Stan-
dard curves were made by performing serial dilutions of pooled
cDNA aliquots. The expressions of the genes of interest were nor-
malized by calculating an average value of the housekeeping genes
-actin, Cyclophilin and 2-microglobulin using geNorm software
(Primerdesign, Southampton, USA). Gene expression is expressed
as arbitrary units (AU).
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Fig. 1. Plasma levels of inﬂammatory mediators of healthy control subjects and
NSCLC patients. Patient with pre-cachexia have an increased inﬂammatory proﬁle
compared with healthy controls. CRP: C-reactive protein (g/ml); sTNF-R1: soluble
Tumor Necrosis Factor receptor 1 (sTNF-R1) (g/ml); ﬁbrinogen (g/l) and albumin
healthy controls (Table 2).
%
pr
ed
ic
te
d
V
O
2p
ea
k
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140   *14 C.M. Op den Kamp et al. / L
.7. 26S proteasome activity assay
The method used for determining peptidase activity of the 20S
ubunit of the 26S proteasome was described previously [20,21].
he protocol was slightly modiﬁed to allow analysis of small human
uscle biopsies. To isolate the 20S proteasome, muscle biop-
ies were homogenized in 10 volumes of ice-cold buffer (pH 7.5)
ontaining 50 mM Tris, 5 mM MgCl2, 250 mM sucrose, 1 mM DTT
nd protease inhibitors (10 g/ml antipain, aprotinin, leupeptin
nd pepstatin A, 0.2 mM PMSF) using a Yellowline homogenizer
IKA Works, Wilmington, NC, USA). Proteasomes were isolated by
equential (ultra) centrifugation steps and the protein concentra-
ion in the proteasome fractions was measured with the Bio-Rad
rotein assay (Bio-Rad, Veenendaal, The Netherlands), using bovine
erum albumin as standard. The peptidase activities of the 20S
roteasome were determined ﬂuorometrically by measuring the
ydrolysis of the ﬂuorogenic substrates Succinyl-Leu-Leu-Val-Tyr-
-amido-4-methylcoumarin (Suc-LLVY-AMC, Sigma, Zwijndrecht,
he Netherlands) and Benzyloxycarbonyl-Leu-Leu-Glu-7-amido-
-methylcoumarin (Z-LLE-AMC, BIOMOL, Exeter, UK). These
ubstrates are preferentially hydrolyzed by the chymotrypsin-like
nd caspase-like peptidase activities of the 20S proteasome, respec-
ively. Adding the proteasome inhibitor MG132 to the reaction
esulted in complete inhibition of the proteasome peptidase activ-
ties.
.8. Statistics
Because the study design was exploratory, no formal power
alculation was performed. Data was analyzed using Statistical
ackage for the Social Sciences (SPSS version 15 for Windows, SPSS
nc., Chicago, IL, USA). Continuous variables were compared using
n independent sample t-test. Pearson Chi-square test was used
or comparing categorical variables. Correlations were evaluated
sing Pearson correlation test. Data is represented as mean ± SD.
igniﬁcance was set at P < 0.05.
. Results
.1. Pre-cachexia in NSCLC is characterized by systemic
nﬂammation without changes in body composition
Baseline characteristics of the study population are shown in
able 1. Patients had signiﬁcantly more weight loss (P = 0.008) than
ealthy controls but the mean observed weight loss was limited,
.e. 3.1% of premorbid body weight (Table 1). Thirteen patients had
5% weight loss, while three patients had 5–10% weight loss. No
hanges were observed in body composition between the study
roups (Table 1). Patients with NSCLC showed a profound pro-
nﬂammatory status as illustrated by increased plasma sTNF-R1
evels (P = 0.032), as well as elevated plasma levels of the positive
cute-phase reactants CRP (P < 0.001) and ﬁbrinogen (P < 0.001).
n addition, plasma levels of the negative acute phase reactant
lbumin were decreased in patients (P < 0.001) (Fig. 1). FEV1 and
EV1/FVC were lower in patients (P < 0.001) but obstruction was
ild as only GOLD stages I–II of chronic obstructive pulmonary
isease (COPD) were observed (Table 1).
.2. Exercise capacity is decreased in pre-cachexia despite normal
hysical activity patterns
Incremental cycle ergometry testing revealed signiﬁcantly
educed peak oxygen consumption in patients (P = 0.010) (Fig. 2).
he V˙O2 peak was not associated with FEV1 (R: 0.41, P = 0.075) and
atients nor healthy controls were restricted by their ventilatory
apacity (VE reserve 44 ± 8% in patients and 18 ± 24% in controls)(mg/ml). *P < 0.05 and **P < 0.001.
(data not shown). Overall physical activity levels were not dif-
ferent and while the proportion of light and moderate activity
was  comparable in both groups, the proportion of high intensity
activity was increased in patients (P = 0.049) (Table 1). No correla-
tion were observed between V˙O2 peak and fat free mass (R: −0.28,
P = 0.909).
3.3. Muscular inﬂammatory signaling and UPS activity is not
altered in patients with NSCLC pre-cachexia
To determine whether NF-B-dependent inﬂammatory sig-
naling and UPS activity were increased in NSCLC pre-cachexia,
expression levels of NF-B target genes IB and TNF and E3
Ub-ligases Atrogin-1/MAFbx and MuRF1 were measured in skele-
tal muscle. Furthermore, in muscle homogenates containing the
isolated 26S proteasome fraction, activity levels of two proteolytic
enzymes of the 20S core subunit were assessed. In Table 2, it is
shown that there were no differences in NF-B, UPS E3-ligase or
26S proteasome activity in pre-cachectic patients compared with                               Controls                               Pa tient s
Fig. 2. Exercise capacity in healthy control subjects and NSCLC patients. The exercise
capacity is signiﬁcantly reduced in patients with NSCLC pre-cachexia compared with
healthy control subjects. *P < 0.05.
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Table 1
Baseline characteristics of healthy control subjects and patients with NSCLC.
Patients (N = 16) Controls (N = 10) P-Value
Gender (males (%)) 93.8 70 0.102
Age  (y)a 65.9 ± 7.5 63.7 ± 5.6 0.427
Weight loss (%)b 3.1 ± 4.4 −0.6 ± 2.0 0.008*
Body mass index (BMI) (kg/m2) 24.2 ± 3.9 27.0 ± 3.6 0.104
Fat  mass index (kg/m2) 6.0 ± 2.7 8.1 ± 3.2 0.079
Fat  free mass index (kg/m2) 17.3 ± 1.7 17.8 ± 2.2 0.612
FEV1 (% predicted)c 78 ± 18 115 ± 22 <0.001*
FEV1/FVCd (%) 62 ± 17 78 ± 4 <0.001*
COPDe GOLD stage (0:I:II) (%) 38:31:31 90:10:0 0.026*
Smoking (current:former:never) (%) 10:70:20 19:81:0 0.165
Physical activity (counts/min) 674 ± 150 694 ± 239 0.831
Low  intensity (% of time) 84 ± 10 89 ± 4.9 0.198
Moderate (% of time) 7 ± 4 7 ± 2 0.819
High  (% of time) 9 ± 1 4 ± 1 0.049*
Stage, n (%)
I–II 11 (69)
IIIA 2 (12)
IIIB 3 (19)
Histology, n (%)
Adenocarcinoma 2 (12)
Squamous cell 8 (50)
Large cell 6 (38)
a Data are represented as means ± SD, all such values.
b Body weight loss in 6 months prior to diagnosis.
c Forced expiratory volume in 1 s.
4
a
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T
Ed Forced vital capacity.
e Chronic obstructive pulmonary disease.
* P < 0.05.
. Discussion
This exploratory study shows that pre-cachexia in NSCLC is
ssociated with signiﬁcantly decreased exercise capacity without
hanges in body composition, and that despite the presence of
ystemic inﬂammation, no inﬂammatory signaling or increased
PS proteolytic activity appears appreciable in skeletal muscle. A
chematic representation of alterations and consequences of pre-
achexia and (preclinical) cachexia is depicted in Fig. 3.
Although several inﬂammatory factors produced by tumor
nd/or host tissues have shown to be sufﬁcient to induce muscle
asting in experimental cancer cachexia [7,8], our data sug-
ests that additional factors or prolonged exposure to systemic
nﬂammation is required to translate systemic to local muscular
nﬂammation in human cachexia. In addition to systemic and local
nﬂammation, increased UPS-mediated proteolysis has convinc-
ngly been demonstrated in preclinical models of cancer cachexia
7–9,11,12].  In line with these ﬁndings, a number of studies in
dvanced stages of human cancer cachexia have also reported
ncreased transcriptional activity of UPS markers in skeletal muscle
able 2
xpression of skeletal muscle inﬂammatory and ubiquitin proteasome system markers.
Baseline characteristic Patients (N = 10)
Inﬂammatory signaling (mRNA expression)
IBa (AU)b 0.24 ± 0.16 
TNF- (AU) 0.21 ± 0.09 
E3  UPS ligases (mRNA expression)
MuRF1 (AU) 0.23 ± 0.25 
Atrogin-1/MAFbx (AU) 0.21 ± 0.10 
26S  proteasome activity
Caspase-like (pmol/g protein/min) 20.38 ± 5.79 
Chymotrypsin-like (pmol/g protein/min) 6.80 ± 3.03 
a Data are represented as means ± SD.
b AU, arbitrary units.[22,23].  However, a small number of studies show that tran-
scriptional activity of UPS markers like E1–E2 enzymes and 26S
proteasome subunits is not increased in patients with <10% weight
loss [24,25].  Furthermore, Smith et al. recently reported no changes
in E3-ligase Atrogin-1/MAFbx and MuRF1 mRNA expression in
gastric cancer patients with limited weight loss [24]. These ﬁnd-
ings are in agreement with the absence of increased expression of
Atrogin-1/MAFbx, MuRF1 and 26S proteasomal activity in the cur-
rent pre-cachectic patient population with NSCLC. Together, this
indicates that UPS-mediated proteolysis is not (yet) increased in
NSCLC pre-cachexia.
The distinct decrease in V˙O2 peak independent of fat free mass
and without changes in daily physical activity indicates that
wasting-independent intrinsic muscular alterations result in exer-
cise intolerance in early stages of NSCLC cachexia. This is an
important ﬁnding as it has been demonstrated that decreased
˙VO2 peak is a strong predictor of mortality and increases the risk
of postoperative complications in early stages of NSCLC [26,27].
As the presence of COPD might have an effect on exercise capac-
ity and COPD is often present in patients with NSCLC due to the
 Controls (N = 8) P-Value
0.26 ± 0.16 0.767
0.25 ± 0.14 0.538
0.18 ± 0.06 0.599
0.28 ± 0.07 0.154
20.72 ± 4.16 0.896
6.34 ± 2.87 0.758
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Fig. 3. Schematic representation of alteration
igarette smoke history, the decreased exercise capacity could be
 result of decreased lung function. Indeed, patients had decreased
ung function capacity but only mild stages of COPD were observed,
.e. only one patient was diagnosed with chronic obstructive pul-
onary disease (COPD) prior to inclusion in this study and only
OLD stages I–II were observed based on the current spirom-
try assessment. Furthermore, despite the presence of COPD,
ecreased exercise capacity was independent of lung function as
llustrated by VE reserves in both groups and absence of cor-
elations between FEV1 and V˙O2 peak. This indicates that other
eterminants are involved in exercise impairment in NSCLC pre-
achexia. The trigger and mechanism of decreased exercise capacity
n NSCLC remains unidentiﬁed but as decreased exercise capac-
ty is often observed in patients with systemic inﬂammation, the
rofound systemic inﬂammatory response in the current patient
opulation is a promising lead [28,29]. It would be of interest
o identify underlying mechanisms of reduced exercise capacity
n patients with NSCLC pre-cachexia to minimize risk of postop-
rative complications and mortality. Furthermore, effectiveness
f intervention strategies, possibly combined in a multimodal
pproach including exercise training and targeted pharmacological
herapies speciﬁcally focused at improving physical performance
hould be studied in randomized controlled trials in patients with
re-cachexia.
In conclusion, this exploratory study shows that decreased exer-
ise capacity independent of lung function (based on FEV1) and
ystemic inﬂammation are present in pre-cachexia in NSCLC but consequences in pre-cachexia and cachexia.
have not (yet) resulted in increased inﬂammatory signaling, UPS-
dependent protein degradation and subsequent wasting of skeletal
muscle. These ﬁndings indicate that molecular proﬁles identiﬁed
in experimental cancer cachexia models are not (yet) present in
NSCLC pre-cachexia. As patients in different stages of cachexia
could beneﬁt from unique intervention strategies, it is of interest to
identify underlying mechanisms of the decreased exercise capac-
ity that is already observed in NSCLC pre-cachexia prior to muscle
catabolism.
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